on Norgine B.V.
Norgine Invests £23 Million in Welsh Medicines Manufacturing Expansion
Norgine B.V., a European specialty pharmaceutical company, has announced a £23 million investment in its Hengoed manufacturing site in Wales, raising total investment to over £50 million since 2022. This expansion, supported by the UK Government's Life Sciences Innovative Manufacturing Fund, aims to boost production and create 44 new skilled jobs.
The funds will enhance the site's production and warehousing capabilities, integrating high-speed and energy-efficient processes to solidify its supply chain amidst global volatility. This investment underlines Norgine's long-term commitment to the region, aligning with its strategy to deliver medicines efficiently across Europe.
Norgine's operational growth includes partnerships with Cardiff University for student placements, further investing in regional skills and sustainable manufacturing practices powered by low-carbon electricity. The initiative reflects Norgine's dedication to innovation and resilience in healthcare delivery.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Norgine B.V. news